CYTL1 was first identified in CD34+ cells derived from bone marrow and cord blood . CD34+ cells are a sub-population of human mononuclear cells that function as hematopoietic stem/progenitor cells . The expression of CYTL1 is not found in mature hematopoietic cells that lack CD34 expression . This discovery was part of an immunogenomics-based screening platform aimed at identifying novel potential cytokines .
CYTL1 has been shown to possess chemotactic activity, particularly towards monocytes and macrophages . It chemoattracts human monocytes via the CCR2B receptor and the ERK signaling pathway . Additionally, CYTL1 has been implicated in the regulation of chondrogenesis, cartilage homeostasis, and osteoarthritis progression . It modulates the expression of Sox9 and insulin-like growth factor 1, which are crucial for cartilage formation and maintenance .
Human recombinant CYTL1, produced through genetic engineering techniques, provides researchers with a valuable tool to study its biological activities and explore its therapeutic potential . CYTL1’s role in immune regulation and tissue repair makes it a promising candidate for developing new treatments for various conditions, including inflammatory arthritis, cardiac fibrosis, and certain types of cancer .
The immunobiological functions of CYTL1 are still being explored, and its potential receptor(s) have not been fully identified . However, studies have shown that CYTL1 can significantly prevent inflammatory arthritis and is required for the maintenance of cartilage homeostasis . High CYTL1 expression has also been observed in cartilaginous tissues and in proteomics analyses of human osteoarthritic patients .